In India, one person has died after being vaccinated against COVID-19, while hundreds of people have been diagnosed with its side effects. However, officials are calling it normal.
India has launched the ‘World’s Largest Campaign’ to vaccinate against coronavirus from January 16. Under it, more than half a million people have been vaccinated so far. However, the death of a medical staff member in Uttar Pradesh on the second day of vaccination raises further questions about the effectiveness and side effects of the vaccine.
Mahipal Singh, an employee of a government hospital in Muradabad district, was vaccinated on Saturday and died on Sunday evening. Mahipal Singh’s son, Vishal, said his father must have been a little unwell before he was vaccinated.
The district administration says his death was not caused by the vaccine. Muradabad Chief Medical Officer MC Garg told the media, “We are trying to find out the cause of his death. The vaccine does not appear to have killed him. He was on duty on Saturday night and did not have any problems at that time.
The state government, citing the post-mortem report of the deceased, said that he died of a heart attack while other complications were also found in him. Medical experts, however, have saved his blood samples for further investigation. But the deceased’s son alleged that his father had not undergone a medical check-up before the vaccination. “When I brought him home, he was facing a breathing problem. I would say that whatever happened was due to the vaccine and I hold the government responsible for it, ” the deceased son said.
More than 450 people have been adversely affected by the vaccine, according to data released by the Indian government two days after the vaccination. In several cities, including Delhi, people had to be hospitalized for treatment, most of whom are said to be in stable condition. Most of these people have symptoms such as pain, mild swelling, mild fever or nausea. According to many medical experts, such allergic reactions after vaccination are common.
India’s drug regulator had given emergency permission to the Covishield vaccine manufactured by the Serum Institute of India (SII) along with Bharat Biotech’s indigenous “Covaxin”, after which the government launched a vaccination program in the country from January 16. The Covishield has been developed by Oxford AstraZeneca but is being produced in India.
Many experts have questioned the suitability of the “vaccine” developed by the Indian company Bharat Biotech, saying that third-stage data for the vaccine was not available and that such a vaccine could not be allowed on a trial basis. Bharat Biotech did not even complete the registration of volunteers for the third phase of the trial and one person allegedly died during the experiment.
Despite all these complaints, the government decided to administer both vaccines at the same time, which is being implemented. The government has also made it clear that the person being vaccinated does not have the right to choose the vaccine of his or her choice. There are reports that the central government has chosen the Oxford vaccine for its subordinate hospital staff, while no distinction has been made for others.
Meanwhile, doctors at the Ram Manohar Lohia Hospital in the capital, Delhi, in protest, told the government that they would like to use the Oxford-made Covishield vaccine and would boycott the Indian company’s vaccine. The doctors’ association has sent an official letter to the hospital management in this regard and has also released a copy to the media.